Status:
COMPLETED
Double-blind Placebo Controlled Study of Oxytocin in Fragile X Syndrome
Lead Sponsor:
Stanford University
Conditions:
Fragile X Syndrome
Eligibility:
MALE
13-29 years
Phase:
PHASE2
Brief Summary
The purpose of this study is to determine whether the medication oxytocin is an effective and tolerable treatment in adolescent males with fragile X syndrome (FraX) for improving socially appropriate ...
Detailed Description
Twelve male adolescent (13-24 years) subjects with confirmed genetic diagnosis of FraX (full mutation) will participate in this randomized double-blind placebo-controlled study. They will receive a do...
Eligibility Criteria
Inclusion
- Confirmed genetic diagnosis of Fragile X (FraX) (full mutation).
- Male (who have more serious effects due to the X chromosome nature of the disorder)
- Age 13-29 years.
- Parent of adolescent must be willing to sign informed consent.
- Intelligence Quotient (IQ) \> 42.
Exclusion
- Cardiac risk factors.
- Medication exclusions: opiates or opiate antagonists, corticosteroids, typical or atypical antipsychotics.
Key Trial Info
Start Date :
February 1 2007
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
January 1 2010
Estimated Enrollment :
10 Patients enrolled
Trial Details
Trial ID
NCT01254045
Start Date
February 1 2007
End Date
January 1 2010
Last Update
March 18 2020
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Stanford University School of Medicine
Stanford, California, United States, 94305